Top 5 bladder cancer articles of 2019

Slideshow

The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.

Related Videos
Ryan L. Steinberg, MD, answers a question during a Zoom video interview
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Related Content
FDA accepts BLA for subcutaneous nivolumab in solid tumors

FDA accepts BLA for subcutaneous nivolumab in solid tumors

May 7th 2024
Article

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.

medical depiction of bladder cancer

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

May 31st 2023
Podcast

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Nivolumab plus chemotherapy nears EU approval for urothelial carcinoma

Nivolumab plus chemotherapy nears EU approval for urothelial carcinoma

April 26th 2024
Article

A decision regarding EU marketing authorization is expected by June 2024.

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

March 29th 2022
Podcast

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

FDA approves nogapendekin alfa inbakicept plus BCG for NMIBC

FDA approves nogapendekin alfa inbakicept plus BCG for NMIBC

April 23rd 2024
Article

The approval is supported by findings of the ongoing QUILT-3.032 trial, assessing nogapendekin alfa inbakicept (N-803) plus BCG in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Clinical trial program of nadofaragene firadenovec in NMIBC expands

Clinical trial program of nadofaragene firadenovec in NMIBC expands

April 16th 2024
Article

The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.

© 2024 MJH Life Sciences

All rights reserved.